APELLIS PHARMACEUTICALS INC (APLS)
US03753U1060 - Common Stock
Taking everything into account, APLS scores 3 out of 10 in our fundamental rating. APLS was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of APLS have multiple concerns. APLS is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year APLS has reported negative net income.
In the past year APLS has reported a negative cash flow from operations.
APLS had negative earnings in each of the past 5 years.
In the past 5 years APLS always reported negative operating cash flow.
1.2 Ratios
APLS has a worse Return On Assets (-67.02%) than 63.08% of its industry peers.
APLS has a Return On Equity of -271.73%. This is in the lower half of the industry: APLS underperforms 73.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.02% | ||
| ROE | -271.73% | ||
| ROIC | N/A |
ROA(3y)-79.15%
ROA(5y)-70.33%
ROE(3y)-343.76%
ROE(5y)-418.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of APLS (85.25%) is better than 89.91% of its industry peers.
APLS's Gross Margin has declined in the last couple of years.
APLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.8%
GM growth 5YN/A
2. Health
2.1 Basic Checks
APLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APLS has been increased compared to 1 year ago.
Compared to 5 years ago, APLS has more shares outstanding
Compared to 1 year ago, APLS has an improved debt to assets ratio.
2.2 Solvency
APLS has an Altman-Z score of -0.12. This is a bad value and indicates that APLS is not financially healthy and even has some risk of bankruptcy.
APLS's Altman-Z score of -0.12 is fine compared to the rest of the industry. APLS outperforms 60.34% of its industry peers.
APLS has a Debt/Equity ratio of 1.71. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of APLS (1.71) is worse than 81.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.71 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.12 |
ROIC/WACCN/A
WACC8.68%
2.3 Liquidity
A Current Ratio of 3.10 indicates that APLS has no problem at all paying its short term obligations.
APLS has a Current ratio of 3.10. This is in the lower half of the industry: APLS underperforms 65.47% of its industry peers.
APLS has a Quick Ratio of 2.50. This indicates that APLS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of APLS (2.50) is worse than 71.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.1 | ||
| Quick Ratio | 2.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.92% over the past year.
The Revenue has grown by 425.27% in the past year. This is a very strong growth!
The Revenue has been growing by 16.53% on average over the past years. This is quite good.
EPS 1Y (TTM)26.92%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q51.33%
Revenue 1Y (TTM)425.27%
Revenue growth 3Y16.53%
Revenue growth 5YN/A
Revenue growth Q2Q544.83%
3.2 Future
APLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.80% yearly.
Based on estimates for the next years, APLS will show a very strong growth in Revenue. The Revenue will grow by 40.43% on average per year.
EPS Next Y72.6%
EPS Next 2Y50.81%
EPS Next 3Y42.15%
EPS Next 5Y28.8%
Revenue Next Year103.07%
Revenue Next 2Y73.59%
Revenue Next 3Y60.12%
Revenue Next 5Y40.43%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
APLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
APLS's earnings are expected to grow with 42.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.81%
EPS Next 3Y42.15%
5. Dividend
5.1 Amount
No dividends for APLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APELLIS PHARMACEUTICALS INC
NASDAQ:APLS (4/19/2024, 7:00:00 PM)
After market: 47.53 0 (0%)47.53
+0.02 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.73B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.02% | ||
| ROE | -271.73% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.25% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.71 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.1 | ||
| Quick Ratio | 2.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)26.92%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y72.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)425.27%
Revenue growth 3Y16.53%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y